NCT03559868View on ClinicalTrials.gov

Inhibition of Sterile Inflammation by Digoxin

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

May 5, 2023

Study Completion Date

May 5, 2023

Conditions
Inflammatory Response
Interventions
DRUG

Digoxin

Participants will receive 3 mcg/Kg/day doses of oral digoxin

OTHER

Placebo

Oral placebo

DRUG

Digoxin

Participants will receive 0.15 mcg/Kg/day doses of oral digoxin

Trial Locations (1)

06520

Yale Centre of Clinical Investigation, New Haven

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Yale University

OTHER

NCT03559868 - Inhibition of Sterile Inflammation by Digoxin | Biotech Hunter | Biotech Hunter